Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function

Launched by PHILIPPE KLEE, MD-PHD · Nov 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a specific substance in the blood, called 1,5-anhydroglucitol, relates to the function of insulin-producing cells in the body, known as beta cells, in obese children. The researchers want to find out if this substance can be used as a new way to measure how well these beta cells are working, especially in children who are obese with or without type 2 diabetes. Participants in the study will have their blood tested and the results will be compared to those of healthy children.

To be eligible for this trial, children aged 12 to 16 years who are considered obese (having a body mass index higher than 97% for their age) can participate. However, children with certain autoimmune diabetes conditions, liver diseases, or those currently taking specific diabetes medications will not be included. If they join the study, participants can expect to provide blood samples and may learn more about their health in the process. This study is currently recruiting participants, and it offers an opportunity to contribute to important research that could improve understanding of diabetes in children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children aged 12 to 16 years
• • Obesity. Defined as a body-mass index above the 97th percentile.
• • Ability to give informed consent as documented by signature
• Exclusion Criteria:
• • Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8.
• • Patients with known liver disease (other than NAFLD)
• • Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion.
• • Patients treated with a drug known to affect liver function